Quarry LP Has $82,000 Stock Holdings in Insulet Co. (NASDAQ:PODD)

Quarry LP increased its position in shares of Insulet Co. (NASDAQ:PODD) by 26.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 354 shares of the medical instruments supplier’s stock after acquiring an additional 74 shares during the quarter. Quarry LP’s holdings in Insulet were worth $82,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Insulet during the second quarter valued at $99,978,000. Baillie Gifford & Co. grew its stake in Insulet by 30.8% during the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock valued at $380,607,000 after acquiring an additional 443,783 shares in the last quarter. Mizuho Securities USA LLC increased its holdings in shares of Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after purchasing an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares in the last quarter. Finally, Westfield Capital Management Co. LP boosted its holdings in shares of Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the period.

Insulet Trading Down 0.8 %

Shares of Insulet stock opened at $265.46 on Monday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.40. The company’s fifty day simple moving average is $247.48 and its 200-day simple moving average is $217.32. The company has a market cap of $18.62 billion, a price-to-earnings ratio of 45.46, a PEG ratio of 4.12 and a beta of 1.21. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of research analyst reports. Sanford C. Bernstein assumed coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Raymond James lifted their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Citigroup upped their target price on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Canaccord Genuity Group boosted their price target on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Barclays raised their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.